Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Rocket Pharmaceuticals, Inc. RCKT
$19.86
-$0.44 (-2.22%)
На 18:00, 12 мая 2023
+159.32%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
1644226584.00000000
-
week52high
23.48
-
week52low
7.57
-
Revenue
0
-
P/E TTM
-7
-
Beta
1.22422100
-
EPS
-3.21000000
-
Last Dividend
0.00000000
-
Next Earnings Date
03 мая 2023 г. в 10:59
Описание компании
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure. It has license agreements with Fred Hutchinson Cancer Research Center; Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; CIEMAT and UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. is headquartered in Cranbury, New Jersey.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Raymond James | Outperform | Outperform | 09 авг 2022 г. |
| Stifel | Buy | Buy | 26 июл 2022 г. |
| Raymond James | Outperform | 08 июл 2022 г. | |
| SVB Leerink | Outperform | Outperform | 06 июл 2022 г. |
| SVB Leerink | Outperform | Outperform | 20 мая 2022 г. |
| UBS | Buy | Buy | 27 сент 2022 г. |
| Raymond James | Outperform | Outperform | 03 окт 2022 г. |
| Chardan Capital | Buy | Buy | 03 окт 2022 г. |
| SVB Leerink | Outperform | Outperform | 30 сент 2022 г. |
| Evercore ISI Group | Outperform | Outperform | 30 сент 2022 г. |
| BTIG | Buy | 01 ноя 2022 г. | |
| Canaccord Genuity | Buy | 08 ноя 2022 г. | |
| Raymond James | Outperform | Outperform | 07 ноя 2022 г. |
| Needham | Buy | Buy | 04 ноя 2022 г. |
| SVB Leerink | Outperform | Outperform | 06 дек 2022 г. |
| B of A Securities | Buy | Buy | 23 дек 2022 г. |
| SVB Leerink | Outperform | Outperform | 22 дек 2022 г. |
| Morgan Stanley | Overweight | 01 февр 2023 г. | |
| SVB Leerink | Outperform | Outperform | 23 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| RTW INVESTMENTS, LP | A | 1 | 1 | 23 дек 2022 г. |
| RTW INVESTMENTS, LP | A | 1 | 1 | 22 дек 2022 г. |
| RTW INVESTMENTS, LP | A | 17628567 | 1355932 | 06 окт 2022 г. |
| Schwartz Jonathan David | A | 22896 | 22896 | 12 авг 2022 г. |
| Militello John | A | 14310 | 14310 | 12 авг 2022 г. |
| Patel Kinnari | A | 52489 | 52489 | 12 авг 2022 г. |
| Wilson Martin | A | 28763 | 28763 | 12 авг 2022 г. |
| Wilson Martin | A | 20318 | 20318 | 12 авг 2022 г. |
| Makker Gotham | A | 5876 | 5876 | 13 июн 2022 г. |
| Makker Gotham | A | 47745 | 47745 | 13 июн 2022 г. |
Новостная лента
Rocket Pharmaceuticals: A Catalyst-Rich Year Ahead
Seeking Alpha
11 мая 2023 г. в 14:34
Today, we peek back in on Rocket Pharmaceuticals, Inc. for the first time in 2023. The company is seeing some momentum from positive trial developments and new-found enthusiasm from the analyst community so far here in May.
Rocket Pharmaceuticals: Promising Gene Therapy Play With Discounted Entry Point
Seeking Alpha
16 февр 2023 г. в 12:32
Rocket Pharmaceuticals stock trades at ~$19.5 today - back in December 2021 it had hit highs of >$60. The highs were achieved when Rocket's in vivo gene therapy showed promise treating patients with a rare genetic heart condition known as Danon Disease.
Rocket Pharmaceuticals Has A Lot More Upside
Seeking Alpha
16 февр 2023 г. в 11:09
Rocket Pharmaceuticals, Inc. performed beautifully for me in the last half year. They have a number of catalysts in the next few months.
Wall Street Analysts Think Rocket Pharmaceuticals (RCKT) Could Surge 163.35%: Read This Before Placing a Bet
Zacks Investment Research
23 янв 2023 г. в 11:17
The mean of analysts' price targets for Rocket Pharmaceuticals (RCKT) points to a 163.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Rocket Pharmaceuticals to Present at 41st Annual J.P. Morgan Healthcare Conference
Business Wire
03 янв 2023 г. в 16:01
CRANBURY, N.J.--( BUSINESS WIRE )--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders with high unmet need, today announces that Gaurav Shah, M.D., Chief Executive Officer, is scheduled to present at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023, at 2:15 p.m. PT.